NEW YORK (GenomeWeb News) - Rules-Based Medicine and EMD Chemicals said today that they are partnering to develop and distribute immunoassay products for use on Luminex’s xMAP platform.
Under the terms of the agreement, biomarker testing firm RBM is providing EMD, a subsidiary of Germany’s Merck KGaA, exclusive distribution rights to its catalog of quantitative protein multiplex assays.
EMD will market RBM’s testing content in co-branded multi-analyte kits under its Novagen brand.
The kits will be available in the middle of 2008 and will be marketed to pharmaceutical and biotechnology companies and universities.
The agreement follows EMD’s announcement last week that it had signed a deal with Luminex to use the xMAP platform for multiplex immunoassays.